Octant

Annexon Appoints Industry Veteran, Dr. Rick Artis, as Chief Scientific Officer to Support the Advancement and Expansion of Complement-focused Portfolio

Retrieved on: 
Friday, January 6, 2023
Yale University, CSO, Doctor of Philosophy, Research, Genentech, Brain, Science, Berkeley, Octant, Patient, Eye, University, Plexxikon, Chemistry, Marketing, Pharmaceutical industry

“The next few years are poised to be transformational for our company as we advance our extensive complement pipeline, with several mid-to-late-stage trials underway.

Key Points: 
  • “The next few years are poised to be transformational for our company as we advance our extensive complement pipeline, with several mid-to-late-stage trials underway.
  • It’s a pleasure to welcome Rick back to the Annexon team to lead our research efforts as CSO.
  • “Annexon has built an impressive pipeline of classical complement inhibitors for the body, brain and eye,” said Dr. Artis.
  • I am thrilled to partner with the team to continue building upon the pioneering research at Annexon to address complement-mediated diseases.”

Zymergen Expands Agreement with Octant to Scale Next-Generation Drug Discovery Platform

Retrieved on: 
Thursday, July 14, 2022
SEC, Security (finance), U.S. Securities and Exchange Commission, Therapy, GLOBE, Private Securities Litigation Reform Act, Drug discovery, Forward-looking statement, Automation, Technology, Protein, RACS, Company, RAC, Efficiency, Growth, Synthetic biology, Risk management, Fine chemical, Octant

EMERYVILLE, Calif., July 14, 2022 (GLOBE NEWSWIRE) -- Zymergen Inc. (Zymergen or the Company) today announced it has expanded its agreement with Octant to further scale their next-generation platform to develop breakthrough medicines.

Key Points: 
  • EMERYVILLE, Calif., July 14, 2022 (GLOBE NEWSWIRE) -- Zymergen Inc. (Zymergen or the Company) today announced it has expanded its agreement with Octant to further scale their next-generation platform to develop breakthrough medicines.
  • In May, Octant purchased five Reconfigurable Automation Carts, or RACs, to improve the throughput, efficiency, and reliability of operations for its existing platform.
  • Its been an incredible journey to watch this technology develop internally at Zymergen and even more rewarding to now see it outside of Zymergen, supporting other companies missions.
  • Octant is a next-generation therapeutics company integrating novel and scaled experimental technologies (multiplexed measurements and high-throughput synthetic chemistry) with computation to solve complex challenges in drug discovery.

Zymergen Sells Modular Automation System to Octant to Scale Next-Generation Drug Discovery Platform

Retrieved on: 
Thursday, May 26, 2022
Chemistry, Company, Private Securities Litigation Reform Act, U.S. Securities and Exchange Commission, Disease, Synthetic biology, RACS, Efficiency, Genetics, Partnership, Forward-looking statement, Technology, Sale, Therapy, Automation, Protein, RAC, SEC, Drug discovery, Security (finance), GLOBE, Fine chemical, Octant

EMERYVILLE, Calif., May 26, 2022 (GLOBE NEWSWIRE) -- Zymergen Inc. (Zymergen or the Company), today announced it has entered into an agreement with Octant for the sale of a modular automation system to scale Octants next-generation platform to develop breakthrough medicines.

Key Points: 
  • EMERYVILLE, Calif., May 26, 2022 (GLOBE NEWSWIRE) -- Zymergen Inc. (Zymergen or the Company), today announced it has entered into an agreement with Octant for the sale of a modular automation system to scale Octants next-generation platform to develop breakthrough medicines.
  • Zymergens complete automation solution includes modular hardware, modern web-based software, custom and turnkey workflows, and active monitoring and support.
  • Octant is a leading therapeutics company focused on developing drugs that match the complexity of human disease, said Sri Kosuri, Co-founder and Chief Executive Officer of Octant.
  • The initial installation consists of 5 Reconfigurable Automation Carts with plans to expand over time as Octant scales their workflows.

Catalio Capital Management Raises $381 Million for Oversubscribed Third Life Sciences Fund

Retrieved on: 
Tuesday, May 3, 2022
Professional Services, Health, Other Health, Other Science, Finance, Science, Biotechnology, Nexus, Investment, LabCorp, Forty-seven rōnin, Fred Hutchinson Cancer Research Center, NASDAQ, Fund, Partnership, CMPS, NYSE, Patient, Bristol Myers Squibb, Cancer, Gilead, Celgene, Oaktree Capital Management, Juno Therapeutics, Johns Hopkins University, Exact sciences, EfTEN Real Estate Fund III, Biomedical technology, Johns Hopkins, Therapy, Growth, LH, IPO, Johns Hopkins School of Medicine, Foundation, Financial services, Pharmaceutical industry, Fine chemical, LP, Research, Octant, Series

Catalio Capital Management, LP (Catalio), a leading multi-strategy life sciences investment firm, today announced the successful close of its third venture fund, Catalio Nexus Fund III (Fund III or the Fund), with more than $381 million in total capital commitments, exceeding its original $300 million target.

Key Points: 
  • Catalio Capital Management, LP (Catalio), a leading multi-strategy life sciences investment firm, today announced the successful close of its third venture fund, Catalio Nexus Fund III (Fund III or the Fund), with more than $381 million in total capital commitments, exceeding its original $300 million target.
  • The Fund received significant backing from current Catalio investors and a number of new, global institutional investors, foundations and endowments.
  • Previously, Catalio raised $15 million for Nexus Fund I and $100 million for Nexus Fund II.
  • Catalio Capital Management, LP, is a multi-strategy life sciences investment firm that focuses on breakthrough biomedical technology companies developing the next generation of drugs, devices, diagnostics and data-driven insights.

Octant Raises $80 Million Series B Round to Support Expansion of Next-Generation Drug Discovery Platform, Announces Collaboration with Bristol Myers Squibb and Key Appointments

Retrieved on: 
Thursday, April 21, 2022
Biotechnology, Other Health, Health, Pharmaceutical, Clinical Trials, Protein, Board, McGovern Institute for Brain Research, Howard Hughes Medical Institute, MIT, Berkeley, Genetics, Coronavirus Scientific Advisory Board (Turkey), Plexxikon, Genentech, Research, Genomics, Yale University, Psychiatry, Cognitive science, Elan, Doctor of Philosophy, Drug discovery, Stanford University, Lists of diseases, Patient, Harvard College, Series, Allen & Company, CSO, Genome, Harvard University, Informatics, Physics, Molecular Discovery, DMS, Bristol Myers Squibb, Biology, Eukaryote, Partnership, University, James, Senior, CRISPR, Partner (business rank), Therapy, Broad Institute, Biological engineering, Synthetic biology, Pharmaceutical industry, Fine chemical, Chemistry, Brain, Octant, Neuroscience

In addition to Catalio, the Series B financing included participation from Bristol Myers Squibb, and existing investors Andreessen Horowitz Bio Fund, Allen & Co., and 50 Years VC.

Key Points: 
  • In addition to Catalio, the Series B financing included participation from Bristol Myers Squibb, and existing investors Andreessen Horowitz Bio Fund, Allen & Co., and 50 Years VC.
  • Octant also plans to develop multiple additional therapeutic programs in small molecule chaperone therapies for rare genetic diseases.
  • Immunogenetics and immunopharmacology are among the most complex areas in biology and drug discovery, with potential to impact countless patients, continued Kosuri.
  • As Chief Scientific Officer, Rick Artis will be responsible for Octant's chemistry function and drug discovery and development programs.

Twist Bioscience Launches 96-Plex Library Prep Kit for Low Pass High Throughput Next-Generation Sequencing

Retrieved on: 
Monday, December 20, 2021
Other Health, Research, General Health, Pharmaceutical, Technology, Hospitals, Genetics, Science, Nanotechnology, Biotechnology, Medical Supplies, Health, Method, U.S. Securities and Exchange Commission, Agriculture, Idiopathic pulmonary fibrosis, Genome informatics, Genomics, NGS, Biology, Genome, Private Securities Litigation Reform Act, Scripps Research, Acquisition, Annual report, NASDAQ, Doctor of Philosophy, Risk, SEC, Silicon, Associate professor, Drug discovery, Octant, CEO, Engineering, IPF, DNA, Associate, Security (finance), Twist Bioscience, Synthetic biology, Martek Biosciences Corporation, GBS, Technology, Translational Genomics Research Institute, Fine chemical, Neurogenomics

Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of synthetic DNA using its silicon platform, today announced the launch of the Twist 96-Plex Library Prep Kit, a high-performance, cost-effective preparation kit for next-generation sequencing (NGS).

Key Points: 
  • Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of synthetic DNA using its silicon platform, today announced the launch of the Twist 96-Plex Library Prep Kit, a high-performance, cost-effective preparation kit for next-generation sequencing (NGS).
  • We found the Twist 96-Plex Library Prep Kit!
  • Library preparation is a major bottleneck for sequencing workflows, from both a timing and cost perspective.
  • The Twist 96-Plex Library Prep Kit includes a robust PCR-like workflow for ultra-high throughput library construction that allows customers to use a small amount of sequencing data to generate high-quality genotype calls across the entire genome.